CD274 and rectal cancer: Patient 21, who had microsatellite stable, PD-L1-low rectal cancer after two lines of treatment with a 1.1 cm target lesion and a nontarget lesion in the lung, had a CR after treatment with 9 doses of 38 μg autogene cevumeran and atezolizumab with a duration of response of 8.2 months and remained on the study after >3 years as of the clinical data cutoff (40.7 months follow-up).